Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor:A new paradigm?  

作　　者：Castalia Fernandez Arturo Navarro-Martin Andrea Bobo Joaquin Cabrera-Rodriguez Patricia Calvo Rodolfo Chicas-Sett Javier Luna Nuria Rodriguez de Dios Felipe Counago 

机构地区：[1]Department of Radiation Oncology,GenesisCare Madrid,Madrid 28043,Spain [2]Department of Radiation Oncology,Institut Catalád’Oncologia,L’Hospitalet de Llobregat,Barcelona 08908,Spain [3]Department of Radiation Oncology,Hospital Ruber Internacional,Madrid 28034,Spain [4]Department of Radiation Oncology,Hospital Universitario de Badajoz,Badajoz 06080,Spain [5]Department of Radiation Oncology,Hospitalario Clínico Universitario de Santiago de Compostela,Santiago de Compostela 15706,Spain [6]Department of Radiation Oncology,ASCIRES Grupo Biomédico,Valencia 46004,Spain [7]Department of Radiation Oncology,Hospital Fundación Jiménez Díaz,Madrid 28040,Spain [8]Department of Radiation Oncology,Hospital del Mar,Barcelona 08003,Spain [9]Department of Radiation Oncology,Hospital Universitario Quironsalud Madrid,Madrid 28223,Spain [10]Department of Radiation Oncology,Hospital La Luz,Madrid 28223,Spain [11]Department of Medicine,School of Biomedical Sciences,Universidad Europea,Madrid 28223,Spain

出　　处：《World Journal of Clinical Oncology》2022年第2期101-115,共15页世界临床肿瘤学杂志（英文版）

摘　　要：Stereotactic ablative body radiotherapy(SABR)is an effective technique comparable to surgery in terms of local control and efficacy in early stages of non-small cell lung cancer(NSCLC)and pulmonary metastasis.Several fractionation schemes have proven to be safe and effective,including the single fraction(SF)scheme.SF is an option costeffectiveness,more convenience and comfortable for the patient and flexible in terms of its management combined with systemic treatments.The outbreak of the severe acute respiratory syndrome coronavirus 2 pandemic has driven this not new but underutilized paradigm,recommending this option to minimize patients’visits to hospital.SF SABR already has a long experience,strong evidence and sufficient maturity to reliably evaluate outcomes in peripheral primary NSCLC and there are promising outcomes in pulmonary metastases,making it a valid treatment option;although its use in central locations,synchronous and recurrencies tumors requires more prospective safety and efficacy studies.The SABR radiobiology study,together with the combination with systemic therapies,(targeted therapies and immunotherapy)is a direction of research in both advanced disease and early stages whose future includes SF.

关 键 词：Stereotactic body radiotherapy Sterotactic ablative body radiotherapy RADIOSURGERY Non-small cell lung cancer Lung cancer Lung metastases 

分 类 号：R73[医药卫生—肿瘤]